AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Innoviva Q2 revenue $67.3mln, IST sales up 54% YoY to $29mln.
ByAinvest
Wednesday, Aug 6, 2025 4:26 pm ET1min read
• Innoviva reports Q2 2025 financial results, $67.3mln revenue • IST U.S. net product sales reach $29mln, 54% YoY growth • ZEVTERA launched in U.S., Zoliflodacin NDA accepted by FDA • PDUFA date set for December 15, 2025
Innoviva Inc. (NASDAQ: IVA) reported its Q2 2025 financial results, showcasing robust performance and significant milestones. The company reported total revenue of $67.3 million, marking a 54% year-over-year (YoY) growth in U.S. net product sales, which reached $29 million. This strong performance was driven by the successful launch of ZEVTERA in the U.S. market and the acceptance of Zoliflodacin's New Drug Application (NDA) by the FDA.The Q2 results highlight Innoviva's commitment to innovation and expansion in the biopharmaceutical sector. The company's ZEVTERA launch in the U.S. represents a significant step forward in its strategic expansion, positioning Innoviva to capitalize on the growing demand for advanced therapeutic solutions. Additionally, the acceptance of Zoliflodacin's NDA by the FDA sets the stage for potential approvals and commercialization in the future.
Innoviva's financial highlights for Q2 2025 include:
- Total revenue of $67.3 million, up from $43.5 million in Q2 2024, representing a 54% YoY growth.
- U.S. net product sales of $29 million, a 54% YoY increase from $18.8 million in Q2 2024.
- The company's gross margin improved significantly, reaching 35% (non-GAAP) compared to 28% in Q2 2024.
Looking ahead, Innoviva has set a PDUFA date of December 15, 2025, for the review of its Zoliflodacin NDA. This regulatory milestone is crucial for the company, as it could unlock significant revenue opportunities if approved. The company's strong Q2 performance and strategic initiatives position it well to continue its growth trajectory and capitalize on market opportunities.
References:
[1] https://theoutpost.ai/news-story/enovix-reports-strong-q2-2025-results-launches-ai-1-battery-platform-18554/
[2] https://www.business-standard.com/companies/quarterly-results/jindal-stainless-q1fy26-net-profit-up-10-percent-on-higher-sales-125080601580_1.html
[3] https://www.ainvest.com/news/agios-pharmaceuticals-navigating-pyrukynd-thalassemia-pdufa-sickle-cell-pipeline-risks-valuation-pressure-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet